Premium, high-purity active materials meticulously refined for Japanese biomedical, analytical research, and clinical diagnostic standards.
The Kansai region, particularly Osaka, stands at the absolute vanguard of Japan’s pharmaceutical innovations, life science researches, and regenerative clinical medicine. Backed by the historical legacy of the Doshomachi pharmaceutical district and powered by cutting-edge hubs like the Northern Osaka Health and Science Park (Kento) and Kobe's biomedical cluster, Osaka-based enterprises require chemical inputs of unmatched purity and safety.
As a key regulatory and commercial destination, the Japanese biopharmaceutical market tolerates zero analytical variation. The Cholic Acid Series Products—encompassing primary bile acids, conjugated derivatives, and high-precision bile salts—serve as critical raw materials, active pharmaceutical ingredients (APIs), diagnostic reagents, and cell-culture emulsifiers. To satisfy the demands of local drug formulation labs, analytical CROs, and commercial clinical test kit developers, manufacturers must bridge the gap between heavy volume synthesis and analytical-grade precision.
We analyze user intent from procurement managers across Osaka's prominent medical universities and domestic drug developers. Their priorities remain unambiguous: PMDA compliance, traceability back to sustainable livestock, low endotoxin levels, and structural homogeneity verified by HPLC/GC-MS testing. Addressing these criteria is vital for scaling therapeutic platforms utilizing cholic acids, such as Chenodeoxycholic Acid (CDCA) and Ursodeoxycholic Acid (UDCA).
A comprehensive overview of extraction technology, microbial biocatalysis, and molecular modification methods that define our bile acid series.
Bile acid chemistry has progressed from basic animal-derived extraction to advanced, semi-synthetic modifications and bio-enzymatic transformations. For specialized requirements in the Osaka biomedical industry, we maintain a dual technological roadmap that combines advanced green extraction with modern synthetic engineering:
Our extraction lines utilize supercritical fluids to isolate crude bile acids without damaging the core steroidal skeleton, preventing lipid peroxidation and retaining native chemical stability.
Employing specific bacterial hydroxysteroid dehydrogenases (HSDHs) to control the stereospecific conversion of hydroxyl groups, yielding high-purity CDCA, UDCA, and Deoxycholic Acid.
Proprietary filtration columns and ultrafiltration membranes designed to remove microbial lipopolysaccharides and heavy metals, meeting strict Japanese Pharmacopoeia (JP) standards.
Responding to global ESG regulations and animal welfare demands within Osaka's biotechnology clusters, our R&D is focused on creating cell-free and microbial synthesis routes for cholic acid analogs. By cloning structural genes for pathway enzymes into robust yeast strains, we aim to produce animal-free cholic acid series products. This transition will minimize bio-security risks (such as TSE/BSE concerns) and offer a highly consistent supply chain for future bioprocessing needs.
Chengdu Chenlv Herb Co., Ltd. operates a modern 9,514 m² high-tech extraction and purification facility. Through automated DCS control systems, we ensure batch-to-batch consistency and high operational safety.
For buyers in Osaka, Sakai, and Kyoto, our close proximity to international shipping lanes allows for fast transit. By partnering with leading Kansai logistics hubs, we handle custom clearance, temperature-controlled transport, and door-to-door delivery smoothly, minimizing supply-chain risks for local manufacturing operations.
Established in 2012, Chenlv Herb specializes in the R&D, production, and sales of high-purity botanical extracts and natural pharmaceutical ingredients. Serving sectors from pharmaceuticals and healthcare supplements to animal nutrition and cosmetics, our manufacturing integrates advanced extraction lines with high-efficiency quality control systems.
Request Factory Audit DossierHow the Cholic Acid Series supports key sectors in Osaka's bio-economy.
Used as raw materials for synthesized bile-derived pharmaceuticals like Ursodeoxycholic Acid (UDCA), treating gallstones, biliary cirrhosis, and chronic liver conditions.
Serving as enzymatic substrates and buffer stabilizers in clinical chemistry analyzers, liver function screening kits, and enzyme assays.
Leveraging cholic acid's micellar properties to design liposomes and nanoparticles that improve the solubility and bioavailability of hydrophobic drugs.
Used as dietary additives in veterinary nutrition to assist fat digestion and support metabolic pathways in research models.
Navigating the requirements of Japan's PMDA (Pharmaceuticals and Medical Devices Agency) demands transparent documentation and batch records. Our quality systems align with global compliance needs, offering support for local regulatory steps.
Our operations hold key safety and quality certifications:
Our workflow ensures clear documentation and quality control at every stage, tailored for partners in the Osaka market.
Defining client specifications, purity targets, physical forms (micronized or crystalline), and packaging parameters.
Producing trial batches and verifying specifications using HPLC, NMR, and GC-MS instrumentation.
Optimizing manufacturing protocols within our automated production lines to ensure consistent batch-to-batch quality.
Conducting final testing and releasing certificates of analysis (CoA) detailing purity, heavy metal content, and endotoxin levels.
Select from our complete range of high-purity bile acid salts, modified structures, and natural co-products.
Essential information for procurement professionals and research teams sourcing cholic acid derivatives for the Japanese market.
Chenlv Herb
